Date: 2018-01-17

Type of information: Nomination

Compound: member of the board of directors

Company: Homology Medicines (USA - MA)

Therapeutic area: Rare diseases - Genetic diseases

Type agreement: nomination

Action mechanism:



  • • On January 17, 2018, Homology Medicines announced the appointment of Matthew R. Patterson, Co-Founder, President and Chief Executive Officer of Audentes Therapeutics, to Homology’s Board of Directors. Mr. Patterson is a biotech industry leader with more than 24 years of experience in research, development and commercialization of innovative treatments for rare diseases.
  • ?In addition to his role at Audentes, Mr. Patterson serves as Vice Chairman of the Alliance for Regenerative Medicine. Previously, Mr. Patterson held positions of senior management in both private and public biotechnology companies, including Genzyme Corporation, BioMarin Pharmaceutical and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed, the world’s largest healthcare-dedicated investment firm.

Financial terms:

Latest news:

Is general: Yes